FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.